Federal regulators fast-tracked approval of psychedelic drugs to treat some of the nation’s most stubborn mental health disorders, reopening a debate that has lingered since the counterculture era: ...

A new federal push is sending psychedelic stocks soaring, but the path to profits is far from guaranteed.

After an executive order, the FDA announced it would prioritize the study of some psychedelic drugs for therapeutic use. Which did they choose and why?

The White House psychedelics executive order accelerates research, clinical trials and "Right to Try" access for drugs like psilocybin, MDMA and ibogaine.

Are psychedelics the next big thing?Psychedelics include the drugs LSD, magic mushrooms, peyote, and often ketamine and MDMA ...

UC Davis researchers created brand-new psychedelic-like compounds by shining UV light on amino acid-based molecules. These ...

Robert Kennedy Jr.’s push for more research into psychedelics harkens back to the 1960s, when Harvard Professor Timothy Leary ...

The Lancet published an Editorial on reviving research into psychedelics for mental health conditions, observing that “the ...

Psychedelics are having a moment — in labs, in legislatures and in mental health spaces. But how does the U.S. public ...

Trump’s orders move the U.S. a few steps closer to more widespread research on and use of two sets of controversial yet promising drugs, psychedelic and cannabis products ...

The order will open the door for more research into psychedelic drugs, including ibogaine, sources told CBS News earlier this week.